Wellington Management Group LLP Has $405,000 Position in DaVita Inc. (NYSE:DVA)

Wellington Management Group LLP raised its stake in shares of DaVita Inc. (NYSE:DVA) by 9.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,711 shares of the company’s stock after purchasing an additional 227 shares during the period. Wellington Management Group LLP’s holdings in DaVita were worth $405,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of DVA. MML Investors Services LLC grew its stake in DaVita by 1.3% in the 3rd quarter. MML Investors Services LLC now owns 5,300 shares of the company’s stock valued at $869,000 after buying an additional 68 shares during the last quarter. Exchange Traded Concepts LLC grew its position in shares of DaVita by 8.3% in the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company’s stock valued at $133,000 after purchasing an additional 68 shares during the last quarter. Impact Partnership Wealth LLC increased its stake in shares of DaVita by 3.7% in the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company’s stock worth $290,000 after purchasing an additional 70 shares during the period. Contravisory Investment Management Inc. lifted its position in shares of DaVita by 1.2% during the 4th quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company’s stock worth $910,000 after purchasing an additional 73 shares during the last quarter. Finally, Nilsine Partners LLC boosted its stake in DaVita by 0.8% during the 4th quarter. Nilsine Partners LLC now owns 11,160 shares of the company’s stock valued at $1,669,000 after purchasing an additional 92 shares during the period. Institutional investors own 90.12% of the company’s stock.

DaVita Trading Down 3.0 %

Shares of DaVita stock opened at $150.85 on Tuesday. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The company’s fifty day moving average price is $151.61 and its two-hundred day moving average price is $156.51. DaVita Inc. has a 52-week low of $125.64 and a 52-week high of $179.60. The firm has a market capitalization of $12.07 billion, a PE ratio of 14.05, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA) last issued its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, analysts expect that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on DVA. Sanford C. Bernstein set a $184.00 price target on DaVita in a research report on Friday, February 21st. StockNews.com raised shares of DaVita from a “hold” rating to a “buy” rating in a research report on Thursday, April 10th. Barclays increased their price target on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Finally, Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.